Omnicell, Inc.’s (OMCL Quick QuoteOMCL - Free Report) first-quarter 2019 adjusted earnings per share (EPS) of 61 cents outpaced the Zacks Consensus Estimate of 41 cents.

 

Adjusted EPS skyrocketed 110.3% from the year-ago figure and also surpassed the company’s guided range of 38-43 cents.

 

 

The Zacks Rank #3 (Hold) company’s adjusted revenues in the first quarter increased 10.9% year over year to $202.5 million. The top line also surpassed the Zacks Consensus Estimate by of $199.4 million.

 

On a segmental basis, Product revenues increased 11.4% year over year to $145.6 million in the reported quarter.

 

Moreover, Service and other revenues climbed 9.5% year over year to $56.9 million.

 

 

In the quarter under review, Omnicell's adjusted gross profit rose 16.7% to $100.6 million. Adjusted gross margin expanded 250 basis points (bps) to 49.7%.

 

Adjusted operating profit totaled $26.2 million, up significantly by 78.5% from the prior-year quarter. Adjusted operating margin in the first quarter rose 490 bps to 13%.

 

SG&A expenses escalated 4.6% year over year to $68.3 million. However, research and development expenses declined 2.8% year over year to $16.1 million. Adjusted operating expenses were $74.4 million in the first quarter, up 4% year over year.

 

 

Omnicell exited the first quarter with cash and cash equivalents of $77.2 million compared with $67.2 million at the end of 2018.

 

 

For the second quarter of 2019, Omnicell expects adjusted revenues between $211 million and $217 million. The Zacks Consensus Estimate stands at $212.7 million, within the guided range.

 

On an adjusted basis, product revenues are expected between $153 million and $158 million, while service revenues are projected within $58-$59 million.

 

Second-quarter adjusted EPS is expected in the band of 61-66 cents. The Zacks Consensus Estimate stands at 56 cents, below the projected range.

 

For 2019, adjusted revenues are expected within $880-$900 million. The Zacks Consensus Estimate stands at $892.3 million, within the guided range.

 

Product revenues for the full year are projected within $652-$668 million, while service revenues are expected between $228 million and $232 million. Moreover, product bookings are anticipated in the $745-$780 million range.

 

Adjusted EPS are expected between $2.62 and $2.82 for 2019. The Zacks Consensus Estimate stands at $2.52, below the guided range.

 

 

Omnicell delivered impressive first-quarter 2019 results. The company continued to see solid segmental contributions. Its solid year-over-year EPS growth is a major positive. Moreover, Omnicell inked various deals for both the XR2 and the IVX Workflow products. It issued an upbeat guidance for second-quarter and 2019.

 

Currently, the company is working on product innovation through R&D. Moving ahead, Omnicell is expected to gain traction from product launches, strategic partnerships and digital transformation. Expansion of gross and operating margins in the quarter is encouraging as well.

 

However, a tough competitive landscape acts as a dampener.

 

 

Some better-ranked stocks that posted solid results this earning season are Stryker Corporation (SYK Quick QuoteSYK - Free Report) , Abbott Laboratories (ABT Quick QuoteABT - Free Report) and CONMED Corporation (CNMD Quick QuoteCNMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

 

Stryker delivered first-quarter 2019 adjusted earnings per share of $1.88, which outpaced the Zacks Consensus Estimate by 2.2%. Meanwhile, revenues of $3.52 billion were in line with the Zacks Consensus Estimate.

 

Abbott’s first-quarter 2019 adjusted earnings came in at 63 cents per share, which exceeded the Zacks Consensus Estimate by 3.3%. First-quarter worldwide sales of  $7.54 billion surpassed the Zacks Consensus Estimate of $7.47 billion.

 

CONMED posted first-quarter 2019 adjusted earnings per share of 57 cents, which outshined the Zacks Consensus Estimate of 54 cents. Revenues of $218.4 million beat the Zacks Consensus Estimate of $213 million.

 

 

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

 

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.